Miltefosine to Treat Mucocutaneous Leishmaniasis (NCT01050907) | Clinical Trial Compass
CompletedPhase 2
Miltefosine to Treat Mucocutaneous Leishmaniasis
United States4 participantsStarted 2010-05
Plain-language summary
The purpose of this Treatment Investigational New Drug application was to make miltefosine available for mucocutaneous leishmaniasis patients presenting in the United States.
If entrance criteria were met, subjects with mucosal or cutaneous leishmaniasis received miltefosine at a targeted dose of 2.5 mg/kg/day for 28 days. During treatment at weeks 1, 2, and 4, the patient returned to the treatment facility to be assessed for adverse events. Blood for transaminase and creatinine values were drawn at the midpoint and at the end of therapy.
Patients returned to the treatment facility to be examined clinically at 6 weeks (ie, 2 weeks after the end of therapy), 3 months (2 months after therapy), and 7 months (6 months after treatment) for mucosal leishmaniasis and cutaneous leishmaniasis patients, and also at 13 months (12 months after treatment) for mucosal leishmaniasis patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Is the subject a male or female at least 18 years of age?
✓. Does the subject weigh at least 30 kg?
✓. Does the subject have a diagnosis of mucosal leishmaniasis or cutaneous leishmaniasis in at least one lesion by at least one of the following methods: 1) positive culture for promastigotes of lesion material, 2) microscopic identification of amastigotes in stained lesion tissue, 3) Polymerase chain reaction of lesion material?
✓. In the opinion of the investigator, is the subject capable of understanding and complying with the protocol?
✓. If female and of child-bearing potential, did the subject have a negative pregnancy test during screening and agree to use an acceptable method of birth control during the treatment phase and for 6 months after treatment is completed?
✓. Has the patient signed informed consent?
Exclusion criteria
✕. Is the subject a female who is breast-feeding?
✕. Does the subject have a clinically significant medical disorder?
What they're measuring
1
Number of Participants With Clinical Cure of Lesions
Timeframe: Week 6, Month 3, Month 7, and Month 13
2
Number of Participants With Adverse Events
Timeframe: Up to 7 months for CL; Up to 13 months for ML
✕. In the last 4 weeks up to the present, has the subject received other treatment for leishmaniasis, including any medication with pentavalent antimony; amphotericin B, paromomycin, or imidazoles?